-
1
المؤلفون: Pierre-Alexis Geoffroy, Louise Carton, Nicolas Simon, Benjamin Rolland, Olivier Cottencin, Jonathan Favre, Régis Bordet, Maryse Lapeyre-Mestre
المساهمون: Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 (SCALab), Université de Lille-Centre National de la Recherche Scientifique (CNRS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193 (SCALab), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille
المصدر: Current Pharmaceutical Design
Current Pharmaceutical Design, 2015, Current Pharmaceutical Design, 21 (23), pp.3280-3297. ⟨10.2174/1381612821666150619092903⟩
Scopus-Elsevier
Current Pharmaceutical Design, Bentham Science Publishers, 2015, Current Pharmaceutical Design, 21 (23), pp.3280-3297. ⟨10.2174/1381612821666150619092903⟩مصطلحات موضوعية: Mesh:Off-Label Use, pharmacoepidemiology, [SDV]Life Sciences [q-bio], medicine.medical_treatment, Inappropriate Prescribing, Mesh:Adult, off-label, [SCCO]Cognitive science, Mesh:Adolescent, 0302 clinical medicine, Risk Factors, Mesh:Risk Factors, Mesh:Antipsychotic Agents/therapeutic use, Drug Discovery, Practice Patterns, Physicians', Child, Mesh:Aged, Mesh:Practice Patterns, Mesh:Treatment Outcome, Mesh:Mental Disorders/psychology, Mental Disorders, Age Factors, Middle Aged, Mesh:Inappropriate Prescribing/trends, 3. Good health, Treatment Outcome, Mesh:Age Factors, Anxiety, Aripiprazole, Patient Safety, medicine.symptom, Mesh:Mental Disorders/drug therapy, Mesh:Antipsychotic Agents/adverse effects, Mesh:Patient Safety, Antipsychotic Agents, Mesh:Risk Assessment, medicine.drug, Adult, safety, medicine.medical_specialty, Adolescent, Mesh:Child, Mesh:Young Adult, Drug Prescriptions, Risk Assessment, elderly, Young Adult, 03 medical and health sciences, children, stomatognathic system, Mesh:Middle Aged, medicine, Humans, Adults, Attention deficit hyperactivity disorder, Medical prescription, Antipsychotic, Psychiatry, Aged, Pharmacology, Risperidone, business.industry, Off-Label Use, Mesh:Drug Prescriptions, medicine.disease, 030227 psychiatry, antipsychotics, Mesh:Humans, stomatognathic diseases, Mood disorders, Mesh:Physicians''/trends, Quetiapine, business, Mesh:Mental Disorders/diagnosis, 030217 neurology & neurosurgery
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea35d614bfaac7fb7f37eff90b3efd11
https://doi.org/10.2174/1381612821666150619092903